Your Article Summary
See Latest ArticlesBiovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine
BioVail Corporation, 06/23/09
Biovail Corporation announced that a wholly owned subsidiary has completed the acquisition of the worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman, and the associated intellectual property rights held by Cambridge Laboratories Limited and its affiliates.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline, 12/01/09
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09